Systemic Low-Grade Inflammation and Cardiovascular Disease in Systemic Lupus Erythematosus

Akboğa, Mehmet Kadri; Okutucu, Sercan; Ertem, Ahmet Göktuğ; Şabanoğlu, Cengiz; Demirtaş, Koray; Akdi, Ahmet; Karanfil, Mustafa

doi:10.1177/0003319718794326

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In their immunohistochemical examination, Pomara et al revealed a positive reaction in cardiac myocytes for antibodies anti-TNF-α and interleukins (IL-8, IL-10 and IL-15) associated with subclinical atherosclerosis and myocyte disorders. TNF-α was positively correlated with CVD risk factors in adolescent and adult populations [114][115][116][117].…”

Section: Immune Cellsmentioning

confidence: 96%

Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease

Blachut,

Przywara-Chowaniec,

Tomasik

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Systemic lupus erythematosus is a chronic connective tissue disease associated with an increased risk of premature atherosclerosis. It is estimated that approximately 10% of SLE patients develop significant atherosclerosis each year, which is responsible for premature cardiovascular disease that is largely asymptomatic. This review summarizes the most recent reports from the past few years on biomarkers of atherosclerosis in SLE, mainly focusing on immune markers. Persistent chronic inflammation of the vascular wall is an important cause of cardiovascular disease (CVD) events related to endothelial dysfunction, cell proliferation, impaired production and function of nitric oxide and microangiopathic changes. Studies on pathogenic immune mediators involved in atherosclerosis will be crucial research avenues for preventing CVD.

show abstract

Section: Immune Cellsmentioning

confidence: 96%

Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease

Blachut,

Przywara-Chowaniec,

Tomasik

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…We thank Dr Akboga et al 1 for their interest in our article and for giving us the opportunity to provide additional details that might enhance the understanding of our findings.…”

mentioning

confidence: 96%

“…Dr Akboga et al 1 are correct that several surrogate markers of inflammation, easily obtainable through the blood count, have been described over the last decades. [3][4][5][6] We did not include them in our primary analyses as their current level of scientific evidence to assess inflammation was limited in patients with systemic lupus erythematosus compared with the erythrocyte sedimentation rate, fibrinogen, and C-reactive protein.…”

mentioning

confidence: 99%